With AI to the superdrug: Are companies like Anthropic, Open AI and Co. the better pharmaceutical corporations?
Artificial intelligence promises faster and more precise results in the research of new drugs. This forces established manufacturers to radically rethink their approach.
The use of artificial intelligence in pharmaceutical research is driving radical change among established manufacturers. According to Marcel Salathé, a Swiss AI expert and epidemiologist, the possibility of a tech company like Anthropic acquiring a pharmaceutical company like Novartis is not surprising, given the increasing overlap between the two industries.
Novartis has recently appointed Anthropic's CEO, Dario Amodei, to its board of directors, and is working with Isomorphic Labs, a subsidiary of Alphabet, on AI-powered drug research. Pharmaceutical companies such as Roche and Eli Lilly are investing heavily in AI, with Roche partnering with Nvidia to build a supercomputer platform and Eli Lilly also developing its own AI capabilities.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
